hackint0sh/temp-data huggingface dataset:
protocolSection identificationModule nctId: NCT06321107, orgStudyIdInfo id: GenSci094-304, briefTitle: Long-term Follow-up Safety of a Single Injection of GenSci094 for Ovarian Stimulation Using Daily Recombinant FSH as Reference, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-02-29, primaryCompletionDateStruct date: 2025-08-15, completionDateStruct date: 2025-10-31, studyFirstPostDateStruct date: 2024-03-20, lastUpdatePostDateStruct date: 2024-03-20, sponsorCollaboratorsModule leadSponsor name: Changchun GeneScience Pharmaceutical Co., Ltd., class: INDUSTRY, collaborators name: Sixth Affiliated Hospital, Sun Yat-sen University, descriptionModule briefSummary: The purpose of this study is to evaluate the safety of a single injection of GenSci094 during Controlled Ovarian Stimulation up to 1 year old of the infants from previous studies., conditionsModule conditions: Infertility, designModule studyType: OBSERVATIONAL, designInfo observationalModel: CASE_CONTROL, timePerspective: OTHER, enrollmentInfo count: 158, type: ESTIMATED, armsInterventionsModule, outcomesModule primaryOutcomes measure: Summary of Pregnancy Outcome, secondaryOutcomes measure: neonatal birth outcomes, secondaryOutcomes measure: Infant development, eligibilityModule sex: FEMALE, minimumAge: 20 Years, maximumAge: 39 Years, stdAges: ADULT, contactsLocationsModule locations facility: The Sixth Affiliated Hospital, Sun Yat-sen University Guangdong Gastrointestinal Hospital, status: RECRUITING, city: Guangzhou, state: Guangdong, country: China, geoPoint lat: 23.11667, lon: 113.25, hasResults: False
protocolSection identificationModule nctId: NCT06321094, orgStudyIdInfo id: VERI-ACS, briefTitle: Effect of Vericiguat on Endpoint Events in Acute Coronary Syndrome( ACS）Patients With Ejection Fraction <45%, statusModule overallStatus: RECRUITING, startDateStruct date: 2023-10-01, primaryCompletionDateStruct date: 2025-10-01, completionDateStruct date: 2025-12-01, studyFirstPostDateStruct date: 2024-03-20, lastUpdatePostDateStruct date: 2024-03-20, sponsorCollaboratorsModule leadSponsor name: The First Affiliated Hospital with Nanjing Medical University, class: OTHER, descriptionModule briefSummary: Investigators evaluate whether differences exsit in acute coronary syndrome（ACS） patients with ejection \<45% between participants who take vericiguat regularly and those who donot., conditionsModule conditions: Acute Coronary Syndrome, conditions: Heart Failure With Reduced Ejection Fraction, designModule studyType: INTERVENTIONAL, phases: PHASE4, designInfo allocation: NON_RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 100, type: ESTIMATED, armsInterventionsModule interventions name: Vericiguat, outcomesModule primaryOutcomes measure: a composite of death from cardiovascular causes or first hospitalization for heart failure, secondaryOutcomes measure: results of echocardiogram, secondaryOutcomes measure: the numerical value of NT-proBNP, secondaryOutcomes measure: level of procalcitonin, secondaryOutcomes measure: interleukin-6 level, secondaryOutcomes measure: life quality score, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 90 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: the First Affiliated Hospital of Nanjing Medical University, status: RECRUITING, city: Nanjing, state: Jiangsu, country: China, contacts name: Liansheng Wang, Doctor, role: CONTACT, phone: 85 25 68303830, email: drlswang@njmu.edu.cn, geoPoint lat: 32.06167, lon: 118.77778, hasResults: False
protocolSection identificationModule nctId: NCT06321081, orgStudyIdInfo id: 2023BJYYEC-428-02, briefTitle: ICE Study: Combination of Irinotecan Plus Cetuximab and Envafolimab as a Rechallenge Regimen in mCRC, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-03-01, primaryCompletionDateStruct date: 2026-02-14, completionDateStruct date: 2026-08-14, studyFirstPostDateStruct date: 2024-03-20, lastUpdatePostDateStruct date: 2024-03-20, sponsorCollaboratorsModule leadSponsor name: Beijing Hospital, class: OTHER_GOV, collaborators name: Bethune Charitable Foundation, descriptionModule briefSummary: This is a non-profit phase II, open, clinical study of the combination of irinotecan plus cetuximab and envafolimab as a rechallenge regimen, in pre-treated RAS/BRAF wild type metastatic colorectal cancer patients (according to liquid biopsy at baseline). Patients have been treated in front lines with irinotecan and cetuximab and had a clinical benefit (complete or partial response) from both of them, no matter whether they had treated by any PD-1 inhibitor before., conditionsModule conditions: RAS Mutation, conditions: Metastatic Colorectal Cancer, conditions: MSS, designModule studyType: INTERVENTIONAL, phases: PHASE2, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 60, type: ESTIMATED, armsInterventionsModule interventions name: irinotecan, cetuximab, envafolimab, outcomesModule primaryOutcomes measure: progression free survival, secondaryOutcomes measure: Overal survival, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Beijing Hospital, status: RECRUITING, city: Beijing, state: Beijing, zip: 100730, country: China, contacts name: Yingying Huang, role: CONTACT, phone: 86-10-85136715, email: yinghh@hotmail.com, geoPoint lat: 39.9075, lon: 116.39723, hasResults: False
protocolSection identificationModule nctId: NCT06321068, orgStudyIdInfo id: BAT-1308-003-CR, briefTitle: BAT1308 in Combination With Platinum-containing Chemotherapy is Used for the First-line Treatment of Advanced or Recurrent dMMR Endometrial Cancer, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-04-09, primaryCompletionDateStruct date: 2024-09, completionDateStruct date: 2027-10, studyFirstPostDateStruct date: 2024-03-20, lastUpdatePostDateStruct date: 2024-04-18, sponsorCollaboratorsModule leadSponsor name: Bio-Thera Solutions, class: INDUSTRY, descriptionModule briefSummary: Phase II study: Safety and preliminary efficacy of BAT1308 combined with platinum-containing chemotherapy;Phase III study: Confirmatory safety and efficacy study of BAT1308 combined with platinum-containing chemotherapy for first-line treatment of advanced or recurrent mismatch repair protein-deficient (dMMR) endometrial carcinoma, conditionsModule conditions: Endometrial Cancer, designModule studyType: INTERVENTIONAL, phases: PHASE2, phases: PHASE3, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 140, type: ESTIMATED, armsInterventionsModule interventions name: carboplatin, interventions name: Paclitaxel, interventions name: Recombinant humanized anti-PD-1 monoclonal antibody injection, outcomesModule primaryOutcomes measure: vital signs, primaryOutcomes measure: Physical examination, primaryOutcomes measure: Adverse events, primaryOutcomes measure: Clinical laboratory tests, primaryOutcomes measure: Clinical auxiliary tests, primaryOutcomes measure: Dose-limiting toxicity (DLT), primaryOutcomes measure: Progression Free Survival, secondaryOutcomes measure: Initial efficacy, secondaryOutcomes measure: Pharmacokinetic, secondaryOutcomes measure: Pharmacokinetic, secondaryOutcomes measure: Pharmacokinetic, secondaryOutcomes measure: Pharmacokinetic, secondaryOutcomes measure: Immunogenicity, secondaryOutcomes measure: Immunogenicity, eligibilityModule sex: FEMALE, minimumAge: 18 Years, maximumAge: 75 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Affiliated Cancer Hospital of Chongqing University, status: RECRUITING, city: Chongqing, state: Chongqing, country: China, contacts name: Qi Zhou, role: CONTACT, phone: 86-13708384529, email: qizhou9128@163.com, geoPoint lat: 29.56278, lon: 106.55278, hasResults: False
protocolSection identificationModule nctId: NCT06321042, orgStudyIdInfo id: SYMPHO-EM, briefTitle: Evaluation of the Clinical Outcomes of the Total Knee ps Prosthesis Implanted With the Use of Inertial Sensors, acronym: SYMPHO-EM, statusModule overallStatus: RECRUITING, startDateStruct date: 2023-01-13, primaryCompletionDateStruct date: 2027-01, completionDateStruct date: 2027-03, studyFirstPostDateStruct date: 2024-03-20, lastUpdatePostDateStruct date: 2024-03-20, sponsorCollaboratorsModule leadSponsor name: Istituto Ortopedico Rizzoli, class: OTHER, descriptionModule briefSummary: evaluate the clinical outcome of the implantation of a specific primary TKA model implanted with the aid of inertial sensors for the execution of bone cuts through the administration of questionnaires for the calculation of clinical-functional scores;, conditionsModule conditions: Prosthesis Durability, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: PROSPECTIVE, enrollmentInfo count: 40, type: ESTIMATED, armsInterventionsModule interventions name: Knee arthroplasty, outcomesModule primaryOutcomes measure: Knee Society Score, primaryOutcomes measure: Knee Society Score, primaryOutcomes measure: Knee Society Score, primaryOutcomes measure: Knee Society Score, primaryOutcomes measure: Western Ontario and McMaster Universities Arthritis Index, primaryOutcomes measure: Western Ontario and McMaster Universities Arthritis Index, primaryOutcomes measure: Western Ontario and McMaster Universities Arthritis Index, primaryOutcomes measure: Western Ontario and McMaster Universities Arthritis Index, primaryOutcomes measure: Knee injury and Osteoarthritis Outcome Score, primaryOutcomes measure: Knee injury and Osteoarthritis Outcome Score, primaryOutcomes measure: Knee injury and Osteoarthritis Outcome Score, primaryOutcomes measure: Knee injury and Osteoarthritis Outcome Score, primaryOutcomes measure: 36-Item Short Form Health Survey, primaryOutcomes measure: 36-Item Short Form Health Survey, primaryOutcomes measure: 36-Item Short Form Health Survey, primaryOutcomes measure: 36-Item Short Form Health Survey, primaryOutcomes measure: Forgotten joint score, primaryOutcomes measure: Forgotten joint score, primaryOutcomes measure: Forgotten joint score, primaryOutcomes measure: Forgotten joint score, secondaryOutcomes measure: Radiographic evaluation of prosthetic femoral component positioning, eligibilityModule sex: ALL, minimumAge: 50 Years, maximumAge: 85 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Stefano Zaffagnini, status: RECRUITING, city: Bologna, state: Italia, country: Italy, contacts name: Stefano Zaffagnini, MD, role: CONTACT, phone: 051 6366075, email: stefano.zaffagnini@unibo.it, geoPoint lat: 44.49381, lon: 11.33875, hasResults: False
protocolSection identificationModule nctId: NCT06320990, orgStudyIdInfo id: 0074-24-CB, briefTitle: Chemoprevention With Tamoxifen in Pre-Invasive Pancreas Mucinous Cystic Neoplasms Not Undergoing Immediate Resection, acronym: MCN_Tam, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-05, primaryCompletionDateStruct date: 2026-11, completionDateStruct date: 2027-05, studyFirstPostDateStruct date: 2024-03-20, lastUpdatePostDateStruct date: 2024-03-20, sponsorCollaboratorsModule leadSponsor name: University of Nebraska, class: OTHER, descriptionModule briefSummary: This is an open-label pilot study of tamoxifen as chemoprevention in patients with pancreatic MCN who will not undergo immediate resection. Up to 15 subjects will be enrolled and take tamoxifen 20mg by mouth daily for up to 24 weeks., conditionsModule conditions: Pancreatic Cyst, conditions: Pancreatic Mucinous Cystic Neoplasm, designModule studyType: INTERVENTIONAL, phases: PHASE1, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: PREVENTION, maskingInfo masking: NONE, enrollmentInfo count: 15, type: ESTIMATED, armsInterventionsModule interventions name: Tamoxifen 20mg, outcomesModule primaryOutcomes measure: Feasibility, by adherence rate, primaryOutcomes measure: Feasibility, by retention rate, secondaryOutcomes measure: Objective response rate (ORR) of pancreatic MCN, eligibilityModule sex: ALL, minimumAge: 19 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: University of Nebraska Medical Center, city: Omaha, state: Nebraska, zip: 68198, country: United States, contacts name: Christina Hoy, DNP, role: CONTACT, email: choy@nebraskamed.com, contacts name: Kelsey Klute, MD, role: PRINCIPAL_INVESTIGATOR, geoPoint lat: 41.25626, lon: -95.94043, hasResults: False
protocolSection identificationModule nctId: NCT06320977, orgStudyIdInfo id: ESS/FSA-397/23-2, briefTitle: The Influence of Acute Static Stretching on the Ankle Joint-position Sense of Soccer Players, statusModule overallStatus: COMPLETED, startDateStruct date: 2024-02-12, primaryCompletionDateStruct date: 2024-03-13, completionDateStruct date: 2024-03-29, studyFirstPostDateStruct date: 2024-03-20, lastUpdatePostDateStruct date: 2024-04-09, sponsorCollaboratorsModule leadSponsor name: University Fernando Pessoa, class: OTHER, descriptionModule briefSummary: The aim of this study isto investigate the influence of acute static stretching on the ankle joint position sense of soccer players., conditionsModule conditions: Healthy, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: CROSSOVER, primaryPurpose: HEALTH_SERVICES_RESEARCH, maskingInfo masking: NONE, enrollmentInfo count: 19, type: ACTUAL, armsInterventionsModule interventions name: Static Stretching, outcomesModule primaryOutcomes measure: Absolute angular error, primaryOutcomes measure: Relative angular error, primaryOutcomes measure: Variable angular error, eligibilityModule sex: MALE, minimumAge: 18 Years, maximumAge: 30 Years, stdAges: ADULT, contactsLocationsModule locations facility: Escola Superior de Saúde Fernando Pessoa, city: Porto, zip: 4200-253, country: Portugal, geoPoint lat: 41.14961, lon: -8.61099, hasResults: False
protocolSection identificationModule nctId: NCT06320964, orgStudyIdInfo id: R01HD108252_1, secondaryIdInfos id: R01HD108252, type: NIH, link: https://reporter.nih.gov/quickSearch/R01HD108252, briefTitle: The TARANG Intervention, acronym: TARANG Pilot, statusModule overallStatus: COMPLETED, startDateStruct date: 2023-07-14, primaryCompletionDateStruct date: 2024-01-21, completionDateStruct date: 2024-01-21, studyFirstPostDateStruct date: 2024-03-20, lastUpdatePostDateStruct date: 2024-03-20, sponsorCollaboratorsModule leadSponsor name: University of California, San Francisco, class: OTHER, collaborators name: Network for Engineering and Economics Research and Management, collaborators name: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), collaborators name: Vikalp Sansthan, descriptionModule briefSummary: The mixed methods pilot study aims to evaluate the acceptability, feasibility, and implementation challenges of the TARANG intervention in villages in rural/tribal Rajasthan to inform the study design and operational details for a larger cluster-randomized controlled trial., conditionsModule conditions: Feasibility, conditions: Acceptability, conditions: Family Planning, conditions: Unintended Pregnancy, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: PREVENTION, maskingInfo masking: NONE, enrollmentInfo count: 135, type: ACTUAL, armsInterventionsModule interventions name: TARANG, outcomesModule primaryOutcomes measure: Feasibility of the intervention, primaryOutcomes measure: Acceptability, primaryOutcomes measure: Usefulness, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Vikalp Sansthan, city: Udaipur, state: Rajasthan, country: India, geoPoint lat: 24.58584, lon: 73.71346, hasResults: False
protocolSection identificationModule nctId: NCT06320938, orgStudyIdInfo id: 2024/18, briefTitle: Effectiveness of Neuroscience-based Pain Education in Patients With Chronic Neck Pain, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-04-18, primaryCompletionDateStruct date: 2024-09-15, completionDateStruct date: 2025-03-15, studyFirstPostDateStruct date: 2024-03-20, lastUpdatePostDateStruct date: 2024-03-27, sponsorCollaboratorsModule leadSponsor name: Turkoglu Dr. Kemal Beyazit State Hospital, class: OTHER, descriptionModule briefSummary: The effectiveness of neuroscience-based pain education, myofascial induction technique, and home exercise programs will be compared in patients with chronic neck pain., conditionsModule conditions: Cervical Spine Disease, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: SINGLE, whoMasked: PARTICIPANT, enrollmentInfo count: 60, type: ESTIMATED, armsInterventionsModule interventions name: Neuroscience-Based Pain Education Combined with Home Exercise Program, interventions name: Myofascial Induction Techniques Combined with Home Exercise Program, interventions name: Home Exercises Group, outcomesModule primaryOutcomes measure: Short Form McGill Pain Questionnaire, primaryOutcomes measure: Algometric Digital Measurement, primaryOutcomes measure: Central Sensitization Inventory, primaryOutcomes measure: Head Posture Evaluation, primaryOutcomes measure: Neck Disability Index, primaryOutcomes measure: Pittsburgh Sleep Quality Index, primaryOutcomes measure: 36-Item Short Form Health Survey Questionnaire, primaryOutcomes measure: Pain Catastrophizing Scale, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 60 Years, stdAges: ADULT, contactsLocationsModule locations facility: Türkoğlu Dr. Kemal Beyazıt State Hospital, city: Kahramanmaraş, country: Turkey, geoPoint lat: 37.5847, lon: 36.92641, hasResults: False
protocolSection identificationModule nctId: NCT06320925, orgStudyIdInfo id: SYK-SM-2022-02, briefTitle: SportsPro: Post-Market Clinical Follow Up Study, statusModule overallStatus: RECRUITING, startDateStruct date: 2023-12-05, primaryCompletionDateStruct date: 2024-06-30, completionDateStruct date: 2024-12-01, studyFirstPostDateStruct date: 2024-03-20, lastUpdatePostDateStruct date: 2024-03-22, sponsorCollaboratorsModule leadSponsor name: Stryker Endoscopy, class: INDUSTRY, descriptionModule briefSummary: Retrospective, multi-center, chart review (only to include data that is part of the surgeons' standard practice), conditionsModule conditions: Shoulder Injuries, conditions: Knee Injuries, conditions: Hip Injuries, designModule studyType: OBSERVATIONAL, designInfo observationalModel: OTHER, timePerspective: RETROSPECTIVE, enrollmentInfo count: 1500, type: ESTIMATED, armsInterventionsModule interventions name: Standard of Care Treatment, outcomesModule primaryOutcomes measure: ASES, primaryOutcomes measure: iHOT-12, primaryOutcomes measure: mHHS, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Musculoskeletal-Orthopedic Research and Education Foundation, status: RECRUITING, city: Phoenix, state: Arizona, zip: 85023, country: United States, contacts name: Wafa Mohsin, role: CONTACT, email: wafa.mohsin@more-foundation.org, contacts name: Michael Amini, MD, role: PRINCIPAL_INVESTIGATOR, geoPoint lat: 33.44838, lon: -112.07404, locations facility: Steadman Hawkins Clinic Denver, status: RECRUITING, city: Englewood, state: Colorado, zip: 80112, country: United States, contacts name: Lauren Heylmun, role: CONTACT, email: LAUREN.HEYLMUN@CUANSCHUTZ.EDU, contacts name: James Genuario, MD, role: PRINCIPAL_INVESTIGATOR, geoPoint lat: 39.64777, lon: -104.98776, locations facility: TSAOG Orthopaedics & Spine, status: RECRUITING, city: San Antonio, state: Texas, zip: 78258, country: United States, contacts name: Amanda Strickland, role: CONTACT, email: astrickland@brioresearch.org, contacts name: Robert Hartzler, MD, role: PRINCIPAL_INVESTIGATOR, geoPoint lat: 29.42412, lon: -98.49363, hasResults: False
protocolSection identificationModule nctId: NCT06320912, orgStudyIdInfo id: TIPS01, briefTitle: Efficacy and Safety of Intraparenchymal Portal Vein Covered Stents in Treating Portal Hypertension and Its Complications, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-04-05, primaryCompletionDateStruct date: 2026-06-01, completionDateStruct date: 2026-11-01, studyFirstPostDateStruct date: 2024-03-20, lastUpdatePostDateStruct date: 2024-03-20, sponsorCollaboratorsModule leadSponsor name: Shanghai Shenqi Medical Technology Co., Ltd, class: INDUSTRY, descriptionModule briefSummary: The objective of this study is to assess the non-inferiority of the intraparenchymal portal vein covered stent in terms of safety and efficacy for managing portal hypertension and its related complications, in comparison to the currently available TIPS Covered Stent System by GORE., conditionsModule conditions: Portal Hypertension, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 258, type: ESTIMATED, armsInterventionsModule interventions name: The intraparenchymal portal vein covered stent, interventions name: TIPS Covered Stent System GORE, outcomesModule primaryOutcomes measure: Postoperative Stent Patency Rate, secondaryOutcomes measure: Immediate Postoperative Technical Success Rate, secondaryOutcomes measure: Incidence of Secondary Interventions at 1 Month, 6 Months, and 12 Months Postoperatively, secondaryOutcomes measure: Incidence of Stent Dysfunction at 1 Month, 6 Months, and 12 Months Postoperatively, secondaryOutcomes measure: Incidence of Major Adverse Events (MAE) at 1 Month, 6 Months, and 12 Months Postoperatively, secondaryOutcomes measure: All-Cause Mortality Rates at 1 Month, 6 Months, and 12 Months Postoperatively, secondaryOutcomes measure: Incidence of Grade II or Higher Hepatic Encephalopathy at 1 Month, 6 Months, and 12 Months Postoperatively, secondaryOutcomes measure: Incidence of Portal Hypertension Rebleeding Confirmed by Endoscopy or Clinical Investigator at 1 Month, 6 Months, and 12 Months Postoperatively (For Original Bleeding Subjects Only), secondaryOutcomes measure: Incidence of Ultrasound-Confirmed Recurrence of Grade 2 or Higher Ascites due to Portal Hypertension at 1 Month, 6 Months, and 12 Months Postoperatively (For Subjects with Original Ascites Only), secondaryOutcomes measure: Incidence of Adverse Events/Serious Adverse Events, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 75 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Southern Medical University Nanfang Hospital, city: Guangzhou, state: Guangdong, country: China, contacts name: Jianbo Zhao, role: CONTACT, geoPoint lat: 23.11667, lon: 113.25, hasResults: False